1/9
06:01 am
kzr
Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis
Medium
Report
Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis
12/17
04:35 pm
kzr
Kezar Life Sciences (NASDAQ:KZR) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Kezar Life Sciences (NASDAQ:KZR) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
12/11
04:20 pm
kzr
Kezar Life Sciences (NASDAQ:KZR) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Kezar Life Sciences (NASDAQ:KZR) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/13
01:09 am
kzr
Kezar Life Sciences GAAP EPS of -$1.53 beats by $0.42 [Seeking Alpha]
Low
Report
Kezar Life Sciences GAAP EPS of -$1.53 beats by $0.42 [Seeking Alpha]
11/12
04:01 pm
kzr
Kezar Life Sciences Reports Third Quarter 2025 Financial Results
Low
Report
Kezar Life Sciences Reports Third Quarter 2025 Financial Results
11/7
07:01 am
kzr
Kezar Life Sciences Announces Presentation of PORTOLA Data at the American Association for the Study of Liver Disease (AASLD) – The Liver Meeting® 2025
Low
Report
Kezar Life Sciences Announces Presentation of PORTOLA Data at the American Association for the Study of Liver Disease (AASLD) – The Liver Meeting® 2025
10/18
07:31 am
kzr
Kezar Life Sciences (NASDAQ:KZR) was downgraded by analysts at TD Cowen from a "strong-buy" rating to a "strong sell" rating.
Low
Report
Kezar Life Sciences (NASDAQ:KZR) was downgraded by analysts at TD Cowen from a "strong-buy" rating to a "strong sell" rating.